Deotrim 60 mlOral Suspension

Generic

Sulphamethoxazole + Trimethoprim

Indications

Compound trimethoprim has a bactericidal effect on a variety of Gram-positive and Gram-negative bacteria in vitro, including Streptococcus, Staphylococcus, Pneumococcus, Neisseria, Pasteurella catarrhalis, Escherichia coli, Klebsiella , Proteus, Haemophilus, Salmonella, Shigella, Brucella. ., Nocardia and Bordetella. It has particularly high activity against Haemophilus influenzae, Escherichia coli and Proteus, which makes compound trimethoprim particularly suitable for the treatment of chronic bronchitis and urinary tract infections. Compound trimethoprim plays its bactericidal effect by sequentially blocking two bacterial enzyme systems in the biosynthesis of folinic acid in microorganisms. The resulting synergy explains the high bactericidal activity. Indications are :

• Respiratory tract infections, including acute and chronic bronchitis (treatment and prevention), bronchiectasis, lung abscess, lobar bronchopneumonia and bronchopneumonia, pneumocystis carinii pneumonia, sinusitis and otitis media.
• Urogenital infections, including urethritis, acute and chronic cystitis, pyelonephritis, prostatitis and gonorrhea.
• Gastrointestinal infection, caused by Salmonella typhi and Salmonella paratyphi, including chronic carrier status.
• Other infections, caused by a variety of microorganisms, have been shown to be susceptible to cotrimoxazole, and the therapeutic benefits are believed to outweigh the possible adverse events.
• Such infections include acute and chronic osteomyelitis, acute brucellosis, skin infections including pyoderma, abscesses and wound infections, sepsis, bacillary dysentery and cholera (as an adjunct to fluid and electrolyte supplements), Cardomycosis and mycetoma.

Pharmacology

Cotrimoxazole has broad bactericidal action against gram-positive and gram-negative bacteria, as well as certain protozoa. The bactericidal effect of Co-trimoxazole, which contains Trimethoprim and Sulphamethoxazole in a 1:5 ratio, is mediated by the successive blockage of two bacterial enzyme systems involved in the production of folinic acid in the bacterium.

Dosage & Administration

The following doses of Levamisole are given as a single administration, preferably after a light meal.

• Age 1-4 year: 1 Tablets or 5 ml Syrup
• Age 5-15 year: 2 Tablets or 10 ml Syrup
• Age 16 year and over: 3 Tablets or 15 ml Syrup

In cases of severe hookworm infection it is suggested that a second standard dose be given one or seven days after the first, whichever timing is feasible.

Contraindications

• Hypersensitivity to trimethoprim or sulphonamides.
• Patients with documented megaloblastic anaemia due to folate deficiency.
• Patients showing marked liver parenchymal damage, blood dyscrasia, severe renal insufficiency, glucose 6-phosphate dehydrogenase deficiency.

Side Effect

Crystalluria, allergic responses, haemolysis, thrombocytopenia, neutropenia, agranulocytosis, and other adverse effects have been described seldom with the combination of Sulphamethoxazole and Trimethoprim. Malaise, headache, nausea, and vomiting are some of the less significant side effects. These are usually transitory and do not need therapy discontinuation.

Pregnancy & Lactation

Because sulphonamides travel through the placenta and are secreted in breast milk, they can induce kernicterus during pregnancy and breastfeeding.

Precautions & Warnings

Because the medication interferes with the conversion of Folic acid to Folinic acid, prolonged full-dose therapy with the sulfamethoxazole-trimethoprim combination increases the risk of macrocytic anemia. Folinic acid can be given to reverse this if it happens. When providing this combination to diabetic patients on a sulphonylurea medicine, it's important to keep in mind that the sulphonylurea's effect may be potentiated.

Therapeutic Class

Anti-diarrhoeal Antimicrobial drugs, Sulphonamides & Trimethoprim

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Pharmaceutical Name

Desh Pharmaceuticals Ltd.